Chronic Migraines? Now enrolling for a local investigational study

Clinvest Research is currently studying an investigational CGRP antibody (Eptinezumab) for the prevention of chronic migraines. Qualified participants between the ages 18-65 who have greater than 8 migraines and 15 headache days a month will receive two doses of study drug 12 weeks apart. The study is approximately 36 weeks long and has 10 office visits. Compensation for time and travel may be provided and study related care is at no cost. Call 417-883-7889 to learn more.